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Abstract
Introduction The potent endogenous antimicrobial peptide
human  β-defensin 2 (hBD2) is a crucial mediator of innate
immunity. In addition to direct antimicrobial properties, different
effects on immune cells have been described. In contrast to the
well-documented epithelial β-defensin actions in local
infections, little is known about the leukocyte-released hBD2 in
systemic infectious disorders. This study investigated the basic
expression levels and the ex vivo inducibility of hBD2 mRNA in
peripheral whole blood cells from patients with severe sepsis in
comparison to non-septic critically ill patients and healthy
individuals.
Methods This investigation was a prospective case-control
study performed at a surgical intensive care unit at a university
hospital. A total of 34 individuals were tested: 16 patients with
severe sepsis, 9 critically ill but non-septic patients, and 9
healthy individuals. Serial blood samples were drawn from
septic patients, and singular samples were obtained from
critically ill non-septic patients and healthy controls. hBD2
mRNA levels in peripheral white blood cells were quantified by
real-time polymerase chain reaction in native peripheral blood
cells and following ex vivo endotoxin stimulation. Defensin
plasma levels were quantified by enzyme-linked immunosorbent
assay.
Results Endotoxin-inducible hBD2 mRNA expression was
significantly decreased in patients with severe sepsis compared
to healthy controls and non-septic critically ill patients (0.02
versus 0.95 versus 0.52, p < 0.05, arbitrary units). hBD2 plasma
levels in septic patients were significantly higher compared to
healthy controls and critically ill non-septic patients (541 versus
339 versus 295 pg/ml, p < 0.05).
Conclusion In contrast to healthy individuals and critically ill
non-septic patients, ex vivo inducibility of hBD2 in peripheral
blood cells from septic patients is reduced. Impaired hBD2
inducibility may contribute to the complex immunological
dysfunction in patients with severe sepsis.
Introduction
Endogenous antimicrobial peptides are widely distributed in
various species [1,2]. They are part of the innate immune sys-
tem and their genes are highly conserved throughout the ani-
mal and plant kingdoms. In humans, antimicrobial defensins
are divided into α- and β-defensins according to their molecu-
lar structure. They display a broad antimicrobial effect against
bacteria, fungi, mycobacteria, and coated viruses [2-5].
Defensins act by permeabilising microbial membranes. In addi-
tion, β-defensins are chemotactic for immature dendritic cells
and memory T cells. They regulate cytokine production and
adhesion-molecule expression, stimulate epithelial cell and
fibroblast proliferation, and promote histamine release from
mast cells [6,7].
To date, six human β-defensin genes have been characterised
and located on chromosome 8. The epithelial human β-
defensin 1 (hBD1) gene is constitutively expressed at low
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serum albumin; Cp = crossing point; hBD2 = human β-defensin 2; hHPRT = human hypoxanthine phosphoribosyl-transferase; HLA-DR = human leu-
kocyte antigen-DR; ICU = intensive care unit; IL = interleukin; NF-κB = nuclear factor-kappa B; PCR = polymerase chain reaction; PCT = procalci-
tonin; SOFA = Sepsis-related Organ Failure Assessment.Critical Care    Vol 11 No 1    Book et al.
Page 2 of 8
(page number not for citation purposes)
levels and slightly upregulated following stimulation [8]. In con-
trast, hBD2, hBD3, and hBD4 gene expression is inducible
mainly by various inflammatory stimuli in different cell types [9-
12] The recently described hBD5 and hBD6 represent epidi-
dymis-specific human defensins [13].
There is increasing evidence for the clinical relevance of
defensins. Alpha- and β-defensins contribute to anti-HIV activ-
ity [14,15]. In newborns, respiratory tract β-defensin mRNA
expression is upregulated in response to infection [16]. More-
over, a systemic release of β-defensins in infectious diseases
has been reported [17]. Our own previous experiments
detected hBD2 mRNA expression in white blood cells follow-
ing ex vivo stimulation by endotoxin [18]. In particular, sys-
temic infection underlying syndromes such as severe sepsis
challenges the immune system by constant activation of its
adaptive and innate components. The responsiveness of the
innate immune system, including expression of endogenous
antibiotic peptides like β-defensins, contributes to the final res-
olution of the disease.
The present study investigated hBD2 mRNA levels in native
peripheral white blood cells as well as the ex vivo hBD2
mRNA inducibility in patients with severe sepsis. Additionally,
we determined hBD2 protein plasma levels in patients. The
hypothesis that hBD2 expression is disturbed in patients with
severe sepsis was tested.
Materials and methods
Patients and controls
This study was performed according to the ethical standards
stated in the 1964 Declaration of Helsinki. After approval by
the local ethics committee and receipt of the written informed
consent of either the patient or a close relative, 16 patients
treated on a surgical intensive care unit (ICU) at a university
hospital with the diagnosis of severe sepsis were included in
this prospective case-control study. The diagnosis of severe
sepsis met the criteria of the American College of Chest Phy-
sician/Society of Critical Care Medicine Consensus Confer-
ence Committee [19]. Exclusion criteria were (a) lack of
informed consent, (b) age younger than 18 years, and (c) pre-
existing immunological or haematological diseases. Whole
blood samples were drawn on the day of diagnosis (day 1) and
on the third and fifth days of severe sepsis. A fourth blood sam-
ple was drawn after recovery from severe sepsis at ICU dis-
charge in survivors or at imminent death in the case of non-
survivors (day X).
In addition, two control groups were included: nine non-septic
critically ill ICU patients who were in need of intensive care
and who were without any signs of infection (blood samples
were drawn once during the ICU treatment) and nine healthy
volunteers (blood samples were drawn once). All patients and
volunteers were of German Caucasian origin.
Blood culture and RNA isolation
Whole blood was co-cultured for four hours with 500 pg/ml
lipopolysaccharide contained in the Milenia® ex vivo stimula-
tion kit (Milenia Biotec, Hohe Str. 4–8, 61231 Bad Nauheim,
Germany) at 37°C and 5% CO2. After incubation, the blood
was centrifuged at 1,500 g for five minutes. The supernatant
was stored at -70°C for further analysis. Total RNA was
extracted from whole blood by means of a QIAamp® RNA
Blood Kit (Qiagen, Hilden, Germany) according to the manu-
facturer's instructions and then dissolved in diethylpyrocar-
bonate-treated water and stored at -70°C until further analysis.
Basic hBD2 mRNA levels were investigated using Paxgene®
Blood RNA System tubes (PreAnalytiX; Qiagen GmbH,
Hilden, Germany). For this analysis, 2.5 ml of whole blood was
drawn in Paxgene® tubes and treated as indicated in the man-
ufacturer's instructions. By this method, intracellular RNA was
stabilised until further analysis. RNA isolation was performed
using the Paxgene®  kit according to the manufacturer's
instructions.
cDNA preparation
cDNA was produced as polymerase chain reaction (PCR)
template using 1st Strand cDNA Synthesis Kit for RT-PCR®
(avian myeloblastosis virus [AMV]) (Roche Diagnostics, Sand-
hofer Str. 116, 68305, Mannheim, Germany). The reaction
mixture contained 8.2 μl (approximately 500 ng) of total RNA,
5 mM MgCl2, 1 mM dNTP, 3.2 μg of random primer p(dN)6,
50 units of RNase inhibitor, 20 units of AMV reverse tran-
scriptase, and 1× reaction buffer in a total volume of 20 μl. The
reaction was incubated at 25°C for 10 minutes, 42°C for 60
minutes, and 99°C for 5 minutes and then cooled to 4°C for 5
minutes.
Real-time PCR
The PCR was performed on a LightCycler® instrument (Roche
Diagnostics). For the amplification of hBD2, the reaction mix-
ture included 10 μl of cDNA, 1 μM each primer (forward and
reverse), 0.15 μM each hybridisation probe (labelled with flu-
orescein and LC-Red640; TIB MOLBIOL GmbH, Berlin, Ger-
many), and 1× Lightcycler FastStart MasterPLUS Mix (Roche
Diagnostics) in a total volume of 20 μl. For detection of the
housekeeping gene hHPRT (human hypoxanthine phosphori-
bosyl-transferase), the 20 μl of reaction mixture consisted of 2
μl of cDNA, 2 μl of reaction mix for hHPRT (Roche), and 12 μl
of ddH2O in 1× Lightcycler FastStart MasterPLUS Mix (Roche
Diagonostics). The sequences of primers and hybridisation
probes specific for hBD2 measurement were as follows: for-
ward primer: 5'-CTGATGCCTCTTCCAGGTGT-3'; reverse
primer: 5'-GGAGCCCTTTCTGAATCCG-3'; probes:
5'-GGTATAAACAAATTGGCACCTGTGGTC-FL and
5'-LC Red640 CCCTGGAACAAAATGCTGCAAAA-PH.
The PCRs for hBD2 and hHPRT were conducted in separate
capillaries as duplicates. The reaction was performed asAvailable online http://ccforum.com/content/11/1/R19
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follows: initial denaturation at 95°C for 10 minutes followed by
45 cycles of 95°C for 5 seconds, 55°C for 8 seconds, and
72°C for 10 seconds. The reaction was then cooled at 40°C
for 30 seconds. Fluorescence was monitored at the end of
each 55°C incubation and detected in channel F2/F1. The
crossing point (CP) of each reaction was analysed by the
method of second derivative maximum algorithm (CP  was
defined as cycle number at detection threshold).
Relative quantification analysis
The expression level of hBD2 mRNA in each sample was ana-
lysed by LightCycler Relative Quantification Software (Roche
Diagnostics). The principles and workflows have been
described previously [20]. In summary, the quantity of a target
(hBD2) and a reference (hHPRT) gene is a function of the
PCR efficiency and the sample CP and does not require a
standard curve in each LightCycler analysis run for its determi-
nation. CP value is most reliably proportional to the initial tem-
plate concentration. Differences in PCR efficiency result from
different primers as well as hybridisation probes and can be
corrected by the software. Results are expressed as the tar-
get/reference ratio of each sample normalised by the target/
reference ratio of the calibrator. The calibrator is included in
every run and its ratio is set to a value of 1. This normalisation
provides a constant calibrator point between PCR runs.
Normalised ratio = ET
CpT(C) - CpT(S) × ER
CpR(S) - CpR(C),
where E = efficiency of PCR amplification, T = target gene, R
= reference gene, S = unknown sample, and C = calibrator.
In this experiment, the coefficient file was created by PCR
amplification of hBD2 and hHPRT as the housekeeping gene
in a series of diluted cDNA (relative standard curve) in tripli-
cates. Data of real-time PCR, including calibrator and samples,
were imported into the Relative Quantification Software and
analysed with the Fit Coefficients File. Finally, the normalised
ratios were calculated. These ratios directly reflect the expres-
sion level of hBD2 mRNA.
hBD2 plasma protein quantification
Twenty micrograms of hBD2 polypeptides was diluted in ace-
tic acid to form the 1 μg/μl stock solution and then adjusted to
10 mM Tris/0.5% bovine serum albumin (BSA)/0.05% Tween-
20 to obtain serial concentrations of the hBD2  standard:
2,000 pg/ml, 1,000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml,
and 62.5 pg/ml. Samples were diluted in 1:4 dilution buffer 10
mM Tris/0.5% BSA/0.05% Tween-20. Coating of the stand-
ards and samples was performed in a 96-well plate with 100
μl of phosphate-buffered saline coating buffer at 4°C
overnight.
Thereafter, the plates were blocked with 300 μl of 5% non-fat
bovine milk blocking buffer at 37°C for 2 hours. The goat pol-
yclonal β-defensin 2 antibody (Abcam plc, 332 Cambridge
Science Park, Milton Road, Cambridge, UK) was diluted to 0.5
μg/ml with 5% non-fat bovine milk antibody dilution buffer.
One hundred microlitres was applied to each well. After addi-
tional washing, the peroxidase-conjugated rabbit anti-goat
immunoglobulin G antibody (1:1,200) (Sigma-Aldrich Chemie
GmbH, Eschenstrasse 5, 82024 Taufkirchen, Germany) was
applied to the wells. Plates were covered and incubated at
37°C for two hours. Washing was followed by the addition of
100 μl of ready-to-use tetramethylbenzidine substrate to each
well. The plate was then covered and incubated at room tem-
perature for 0.5 hours. One hundred microlitres of stop solu-
tion was added to each well. Absorbance was measured at
405 nm using a microtiter plate spectrophotometer followed
by an endpoint measurement within one hour.
Human leukocyte antigen-DR quantification on 
circulating monocytes
Flow cytometric human leukocyte antigen-DR (HLA-DR) quan-
tification was performed according to the method of Docke
and colleagues [21]. In brief, this new method quantifies the
number of molecules per monocyte and allows direct compar-
isons between laboratories.
Whole blood cell counts
Leukocyte and monocyte cell counts in whole blood were
quantified routinely by standardised clinical biochemical
methods.
Statistical analysis
Significance levels between groups were examined using the
Kruskal-Wallis test with the Dunn multiple comparison test and
Mann-Whitney U test where indicated. A p value of less than
0.05 was regarded as statistically significant. The time course
of the Sepsis-related Organ Failure Assessment (SOFA)
scores was analysed by two-way analysis of variance
(ANOVA) with repeated measures and Bonferroni post hoc
analysis. Two-way ANOVA with repeated measures was also
used for the time course of hBD2 plasma levels. In contrast,
the non-gaussian distribution of ex vivo inducible defensin
mRNA expression was analysed by the Kruskal-Wallis test.
Correlation of the scores with hBD2 inducibility was tested
using the Spearman test. Statistical power calculations were
performed using an open-access statistical web page [22].
Results
Sixteen patients with severe sepsis were included in this
study. Eight of these patients died from sepsis-induced organ
failure. In addition, nine critically ill but non-septic ICU patients
and nine healthy volunteers were included. Table 1 shows
demographic and clinical data of the patients. Acute Physiol-
ogy and Chronic Health Evaluation II (APACHE II) and Simpli-
fied Acute Physiology Score II scores differed between
Normalised ratio
conc.target sample
con.reference sample
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critically ill non-septic patients and patients with severe sepsis
(p < 0.05, Mann-Whitney test), whereas age did not (p > 0.05,
Mann-Whitney test). Underlying diseases for severe sepsis
were necrotising fasciitis (n = 2; at inclusion, both showed
clinical signs of additional pulmonary infection), faecal perito-
nitis (n = 8), and pneumonia (n = 6). Finally, all patients with
severe sepsis suffered from abdominal or pulmonary infection.
Eight of the nine critically ill non-septic patients were in the
perioperative period after trauma, abdominal or pharyngeal
cancer, or aortic aneurysm rupture with a prolongated postop-
erative recovery. All of these patients except one were treated
with perioperative antibiotic prophylaxis. One patient from this
control group suffered from abacterial pancreatitis without
antibiotic therapy. None of these patients showed clinically or
laboratory signs of infection.
None of the critically ill patients was treated with hydrocorti-
sone. In contrast, 11 patients with severe sepsis were medi-
cated with low-dose hydrocortisone (3 mg/kg body weight per
day) at at least one measuring point. All patients with sepsis
were treated according to guidelines issued by the Surviving
Sepsis Campaign [23].
SOFA score was determined at every time point of blood
drawing in the included patients, and APACHE II score was
calculated at inclusion. The score differences between the
patient groups are illustrated in Table 1. Neither the hBD2
inducibility nor the protein levels showed correlations with
APACHE II or SOFA scores (p > 0.05, Spearman test; data
not shown). hBD2 plasma levels did not show a correlation
with the Horowitz quotient, thrombocyte count, creatinin lev-
els, or the need of use of vasopressors (p > 0.05, Spearman
test; data not shown).
SOFA scores in survivors of severe sepsis were decreased at
day five and the last sampling day compared to non-survivors
(p < 0.05, two-way ANOVA with repeated measures and Bon-
ferroni post hoc analysis; data not shown).
Basic hBD2 mRNA expression was not detectable in periph-
eral blood cells from healthy controls. The basic hBD2 mRNA
expression in survivors and non-survivors of severe sepsis and
critically ill patients was normalised to the leukocyte count of
every blood sample and showed no differences (p > 0.05,
Kruskal-Wallis test with the Dunn multiple comparison test;
Figure 1).
In contrast, hBD2 mRNA was detectable in ex vivo stimulated
cultured whole blood. Endotoxin stimulation (4 hours, 0.5 ng/
ml) induced hBD2 mRNA expression in all groups and led to
low inducibility in patients with severe sepsis. Figure 2 indi-
cates the inducible mRNA expression normalised to leukocyte
count at all measured time points. The inducibility in patients
with severe sepsis was significantly decreased compared to
both other groups (p < 0.05, Kruskal-Wallis test with the Dunn
Table 1
Demographic and clinical data of critically ill non-septic patients and patients with severe sepsis
Critically ill non-septic (n = 9) Severe sepsis (n = 16) p
Median age (years) 68 55 > 0.05
Median APACHE II score at inclusion 12 29 < 0.05
Median SAPS II score at inclusion 27 60 < 0.05
Mechanically ventilated at inclusion (n)5 1 6
Vasopressor treatment at inclusion (n)0 1 3
Median IL-6 plasma levels (ng/l) 18 72 < 0.05
Median procalcitonin plasma levels (μg/l) 0.19 2.01 < 0.05
Antibiotic treatment at inclusion (n)7 1 6
Statistical differences were calculated by Mann-Whitney test. APACHE II, Acute Physiology and Chronic Health Evaluation II; IL-6, interleukin-6; 
SAPS II, Simplified Acute Physiology Score II.
Figure 1
Basic human β-defensin 2 (hBD2) mRNA expression normalised to leu- kocyte count in critically ill non-septic patients and survivors and non- survivors of severe sepsis shows no differences Basic human β-defensin 2 (hBD2) mRNA expression normalised to leu-
kocyte count in critically ill non-septic patients and survivors and non-
survivors of severe sepsis shows no differences. No basic mRNA 
expression was detected in healthy controls (p < 0.05, Kruskal-Wallis 
test with the Dunn multiple comparison test). Data are presented as 
box-and-whisker plots.Available online http://ccforum.com/content/11/1/R19
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multiple comparison test) without differences between survi-
vors and non-survivors of severe sepsis. Despite the limited
number of patients, the statistical power of the comparison of
hBD2 mRNA inducibility between patients with severe sepsis
and controls was 0.95. Hydrocortisone treatment did not
impair the leukocyte count-normalised hBD2 mRNA inducibil-
ity in patients with severe sepsis (p > 0.05, Kruskal-Wallis test
with the Dunn multiple comparison test; Figure 3).
In addition, hBD2 protein concentration was quantified in
plasma at all included time points. hBD2 plasma concentra-
tions in non-septic critically ill patients and healthy controls
were significantly lower compared to patients with severe sep-
sis (p < 0.05, Kruskal-Wallis test with the Dunn multiple com-
parison test; Figure 4). The comparison of hBD2 plasma levels
reached statistical significance at a power of 0.98. No differ-
ences were detected between survivors and non-survivors of
severe sepsis.
hBD2 protein levels showed no correlation with interleukin
(IL)-6 plasma levels in septic patients (p > 0.05, correlation
coefficient r = -0.041, Spearman test; data not shown). In con-
trast, procalcitonin (PCT) plasma levels and hBD2 protein
plasma levels showed a positive correlation in patients with
severe sepsis (p < 0.005, correlation coefficient r = 0.4203,
Spearman test; Figure 5).
The time course of hBD2 plasma protein concentration in
patients with severe sepsis did not differ significantly between
survivors and non-survivors, however it showed considerable
variation between survivors and non-survivors (p > 0.05, two-
way ANOVA with repeated measures; Figure 6).
Figure 2
Ex vivo human β-defensin 2 (hBD2) inducibility in healthy controls, criti- cally ill non-septic patients, and survivors and non-survivors of severe  sepsis Ex vivo human β-defensin 2 (hBD2) inducibility in healthy controls, criti-
cally ill non-septic patients, and survivors and non-survivors of severe 
sepsis. Inducible hBD2 mRNA expression normalised to leukocyte 
count is decreased in survivors and non-survivors of severe sepsis 
compared to healthy controls and critically ill non-septic patients (*p < 
0.05, Kruskal-Wallis test with the Dunn multiple comparison test). Data 
are presented as box-and-whisker plots.
Figure 3
Ex vivo human β-defensin 2 (hBD2) inducibility in patients with severe  sepsis Ex vivo human β-defensin 2 (hBD2) inducibility in patients with severe 
sepsis. Inducible hBD2 mRNA expression normalised to leukocyte 
count shows no differences in cortisone-treated or non-cortisone-
treated patients (p > 0.05, Kruskal-Wallis test with the Dunn multiple 
comparison test). Data are presented as box-and-whisker plots.
Figure 4
Human β-defensin 2 (hBD2) plasma protein concentration in healthy  controls, critically ill non-septic patients, and patients with severe  sepsis Human β-defensin 2 (hBD2) plasma protein concentration in healthy 
controls, critically ill non-septic patients, and patients with severe sep-
sis. Plasma concentration in healthy controls and critically ill non-septic 
patients was significant lower compared to patients with severe sepsis 
(*p < 0.05, Kruskal-Wallis test with the Dunn multiple comparison test). 
Data are presented as box-and-whisker plots.
Figure 5
Human β-defensin 2 (hBD2) plasma protein and procalcitonin (PCT)  levels showed a significant correlation in patients with severe sepsis (p  < 0.005, Spearman test) Human β-defensin 2 (hBD2) plasma protein and procalcitonin (PCT) 
levels showed a significant correlation in patients with severe sepsis (p 
< 0.005, Spearman test).Critical Care    Vol 11 No 1    Book et al.
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HLA-DR quantification was performed in patients with severe
sepsis and non-septic critically ill patients. HLA-DR molecules
on circulating monocytes per cell in non-septic critically ill
patients were significantly higher compared to patients with
severe sepsis (p  < 0.05, Mann-Whitney U  test; data not
shown).
Discussion
The present investigation shows the novel finding of impaired
hBD2 gene inducibility in peripheral cells and elevated plasma
protein concentration in patients with severe sepsis compared
to non-septic critically ill patients and healthy controls. The
meaning of β-defensins for the defence of infections is based
on well-described antimicrobial activities [24,25]. In addition,
β-defensins induce prostaglandin D2 production, degranulate
mast cells, and present chemotactic activities on CCR6-posi-
tive dendritic cells [6,26]. In mice, additional immunomodula-
tory effects have been reported [6,27,28]. These data indicate
their involvement in innate immunity. These reported effects
suggest regulatory or mediatory defensin functions. The role of
antibiotic peptides in the pathogenesis of Crohn's colitis,
cystic fibrosis, and panbronchiolitis has been described
clearly. An effective defence related to levels and inducibility of
defensins has been reported [17,29-33].
The elevated plasma levels of hBD2 in patients with severe
sepsis indicate a higher activity of inflammation compared to
non-septic individuals. Proinflammatory cytokines such as IL-1
and tumour necrosis factor induce hBD2 gene expression in
alveolar macrophages and monocyte-derived epidermis cells
(IL-1) [10,12]. These proinflammatory cytokines, which are
frequently elevated in severe sepsis, are potentially involved in
the upregulation of systemic hBD2 release in sepsis as well.
The decreased hBD2 inducibility in peripheral blood cells was
not associated with decreased plasma levels, suggesting that
peripheral blood cells do not represent the exclusive source of
released hBD2 protein in vivo.
The hBD2 plasma concentration in healthy controls agrees
with findings from other investigations [17,34]. It should be
taken into account that circulating endothelial cells or reticu-
loendothelial cells also represent a possible source of hBD2
[35]. The results for hBD2 mRNA inducibility and the basic
protein plasma levels showed no significant differences
between healthy controls and critically ill non-septic patients.
Median PCT levels were in normal range, indicating a lack of
systemic infection, whereas a median IL-6 of 18 ng/l (normal
is below 15 ng/l) suggested minor systemic inflammatory acti-
vation in the non-septic critically ill patient group. For gene
activation of hBD2 and IL-6, the transcription factor nuclear
factor-kappa B (NF-κB) is crucial. The low IL-6 levels in the
critically ill non-septic group provide a hint for, but are not
proof of, low NF-κB activation in this group. This minor activa-
tion showed no influence on hBD2 inducibility or protein levels
compared to healthy controls. Only the systemic infection in
the severe septic patient group led to changes in gene induc-
ibility and plasma levels. These results underline a specific
impact of systemic infections on hBD2 gene expression and
plasma levels.
The decreased hBD2 mRNA inducibility in peripheral blood
cells of patients with severe sepsis could mirror a serious inhi-
bition of innate immune function. But given that the detected
plasma concentrations were lower than required for bacteri-
cidal/antiviral activity, antimicrobial peptides may not exert
their antimicrobial effects via the bloodstream [36-38]. How-
ever, innate immunity may be impaired not only due to the lack
of direct antimicrobial activity but because of limited immu-
nomodulating effects of defensins.
This immunological imbalance occurring in severe sepsis can
be monitored, among other ways, by HLA-DR quantification on
circulating monocytes. In this manner, the immune compe-
tence of monocytes can be assessed. It is well established
that monocytes with diminished HLA-DR expression are inhib-
ited in some of their main tasks (for example, antigen presen-
tation and mediator production) [39,40]. Indeed, the
investigated patients with severe sepsis showed signs of
immunodepression by decreased HLA-DR expression on cir-
culating monocytes. This finding underlines that sepsis may
contribute to the impaired hBD2 inducibility as reported in the
present investigation.
In this investigation, hydrocortisone treatment did not impair
hBD2 inducibility in patients with severe sepsis. However, at
the present time, there are no consistent data on the influence
of steroid medication on hBD2 inducibility [41-43].
An individual's age can modulate immune function. Activities
of cellular components of innate immunity are impaired at dif-
ferent levels [44-46]. To date, no data assessing antimicrobial
peptide gene expression in the elderly have been collected.
However, in insects, antimicrobial peptide gene expression
Figure 6
Human β-defensin 2 (hBD2) plasma protein concentration at different  time points in patients with severe sepsis Human β-defensin 2 (hBD2) plasma protein concentration at different 
time points in patients with severe sepsis. Time course of hBD2 plasma 
protein concentration in survivors and non-survivors of severe sepsis 
showed no statistical differences (p > 0.05, two-way analysis of vari-
ance with repeated measures). Data are presented as mean ± standard 
error of the mean.Available online http://ccforum.com/content/11/1/R19
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increases with age [47]. The median age of the control group
was significantly lower compared to both other groups. There
was no significant difference of the median age between the
critically ill and the septic patients. Therefore, the differences
between the critically ill and the septic patients concerning
hBD2 mRNA inducibility and plasma levels cannot be
explained by differences in age.
Conclusion
hBD2 inducibility in leukocytes from patients with severe sep-
sis is decreased. This special part of innate immunity is influ-
enced by severe sepsis. The downregulation of inducibility
may contribute to the complex immunological imbalance
occurring in patients with severe sepsis.
The importance of plasmatic hBD2 for patients with severe
sepsis is unclear. In particular, knowledge of the interaction
with mediators and effectors of the immune system is scarce
but of prime importance. To date, the antimicrobial and immu-
nomodulatory activities of hBD2 have been tested only in ex
vivo  settings with limited numbers of additional co-factors.
However, in vivo, hBD2 is an integral component of a set of
effectors that function together in the innate immune line of
defence.
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